奥希替尼辅助治疗 EGFR 突变早期 NSCLC：生活质量影响决策吗？
Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
机构信息
Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado.
出版信息
Clin Cancer Res. 2022 Jun 1;28(11):2204-2205. doi: 10.1158/1078-0432.CCR-22-0116.
Abstract
The ADAURA adjuvant randomized trial demonstrated that osimertinib prolonged DFS. It has now been reported that health-related quality of life (HRQoL) was not adversely affected by adjuvant osimertinib. Does this mean that adjuvant osimertinib should now be standard as we await survival results? See related article by Majem et al., p. 2286.
摘要
ADAURA 辅助随机试验表明奥希替尼可延长无疾病生存期。现在已有报道称，辅助奥希替尼不会对健康相关生活质量（HRQoL）产生不利影响。这是否意味着我们在等待生存结果时，辅助奥希替尼现在应该成为标准治疗？请参阅 Majem 等人的相关文章，第 2286 页。
Zotero 插件